vs
富兰克林柯维（FC）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
Vericel Corp的季度营收约是富兰克林柯维的1.5倍（$92.9M vs $64.0M），Vericel Corp净利率更高（25.0% vs -5.1%，领先30.1%），Vericel Corp同比增速更快（23.3% vs -7.3%），Vericel Corp自由现金流更多（$12.8M vs $-1.6M），过去两年Vericel Corp的营收复合增速更高（34.6% vs 2.2%）
富兰克林柯维总部位于美国犹他州盐湖城，是一家专业培训指导企业，面向各类组织与个人提供领导力提升、个人效能成长与业务执行领域的培训及评估服务。公司由富兰克林奎斯特与柯维领导力中心于1997年合并成立，最为人熟知的产品包括富兰克林柯维规划系统等。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
FC vs VCEL — 直观对比
营收规模更大
VCEL
是对方的1.5倍
$64.0M
营收增速更快
VCEL
高出30.6%
-7.3%
净利率更高
VCEL
高出30.1%
-5.1%
自由现金流更多
VCEL
多$14.5M
$-1.6M
两年增速更快
VCEL
近两年复合增速
2.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $64.0M | $92.9M |
| 净利润 | $-3.3M | $23.2M |
| 毛利率 | 75.5% | 78.7% |
| 营业利润率 | -5.7% | 24.1% |
| 净利率 | -5.1% | 25.0% |
| 营收同比 | -7.3% | 23.3% |
| 净利润同比 | -378.5% | 17.3% |
| 每股收益（稀释后） | $-0.27 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCVCEL
| Q4 25 | $64.0M | $92.9M | ||
| Q3 25 | $71.2M | $67.5M | ||
| Q2 25 | $67.1M | $63.2M | ||
| Q1 25 | $59.6M | $52.6M | ||
| Q4 24 | $69.1M | $75.4M | ||
| Q3 24 | $84.1M | $57.9M | ||
| Q2 24 | $73.4M | $52.7M | ||
| Q1 24 | $61.3M | $51.3M |
净利润FCVCEL
| Q4 25 | $-3.3M | $23.2M | ||
| Q3 25 | $4.4M | $5.1M | ||
| Q2 25 | $-1.4M | $-553.0K | ||
| Q1 25 | $-1.1M | $-11.2M | ||
| Q4 24 | $1.2M | $19.8M | ||
| Q3 24 | $12.0M | $-901.0K | ||
| Q2 24 | $5.7M | $-4.7M | ||
| Q1 24 | $874.0K | $-3.9M |
毛利率FCVCEL
| Q4 25 | 75.5% | 78.7% | ||
| Q3 25 | 75.5% | 73.5% | ||
| Q2 25 | 76.5% | 73.7% | ||
| Q1 25 | 76.7% | 69.0% | ||
| Q4 24 | 76.3% | 77.6% | ||
| Q3 24 | 78.1% | 71.9% | ||
| Q2 24 | 76.6% | 69.5% | ||
| Q1 24 | 76.4% | 68.9% |
营业利润率FCVCEL
| Q4 25 | -5.7% | 24.1% | ||
| Q3 25 | 11.1% | 5.1% | ||
| Q2 25 | -3.3% | -3.2% | ||
| Q1 25 | -2.4% | -24.3% | ||
| Q4 24 | 2.1% | 24.5% | ||
| Q3 24 | 21.3% | -4.3% | ||
| Q2 24 | 11.4% | -11.5% | ||
| Q1 24 | 2.4% | -10.7% |
净利率FCVCEL
| Q4 25 | -5.1% | 25.0% | ||
| Q3 25 | 6.1% | 7.5% | ||
| Q2 25 | -2.1% | -0.9% | ||
| Q1 25 | -1.8% | -21.4% | ||
| Q4 24 | 1.7% | 26.3% | ||
| Q3 24 | 14.2% | -1.6% | ||
| Q2 24 | 7.8% | -8.9% | ||
| Q1 24 | 1.4% | -7.5% |
每股收益（稀释后）FCVCEL
| Q4 25 | $-0.27 | $0.46 | ||
| Q3 25 | $0.34 | $0.10 | ||
| Q2 25 | $-0.11 | $-0.01 | ||
| Q1 25 | $-0.08 | $-0.23 | ||
| Q4 24 | $0.09 | $0.40 | ||
| Q3 24 | $0.89 | $-0.02 | ||
| Q2 24 | $0.43 | $-0.10 | ||
| Q1 24 | $0.06 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.5M | $137.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $54.0M | $354.6M |
| 总资产 | $221.3M | $488.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FCVCEL
| Q4 25 | $17.5M | $137.5M | ||
| Q3 25 | $31.7M | $135.4M | ||
| Q2 25 | $33.7M | $116.9M | ||
| Q1 25 | $40.4M | $112.9M | ||
| Q4 24 | $53.3M | $116.2M | ||
| Q3 24 | $48.7M | $101.7M | ||
| Q2 24 | $36.6M | $102.5M | ||
| Q1 24 | $40.9M | $110.6M |
股东权益FCVCEL
| Q4 25 | $54.0M | $354.6M | ||
| Q3 25 | $66.9M | $321.9M | ||
| Q2 25 | $65.6M | $306.8M | ||
| Q1 25 | $72.5M | $295.5M | ||
| Q4 24 | $80.6M | $292.0M | ||
| Q3 24 | $83.1M | $257.5M | ||
| Q2 24 | $72.2M | $243.0M | ||
| Q1 24 | $70.8M | $233.9M |
总资产FCVCEL
| Q4 25 | $221.3M | $488.0M | ||
| Q3 25 | $242.9M | $453.3M | ||
| Q2 25 | $218.3M | $435.6M | ||
| Q1 25 | $221.3M | $424.6M | ||
| Q4 24 | $239.9M | $432.7M | ||
| Q3 24 | $261.5M | $390.4M | ||
| Q2 24 | $221.0M | $376.8M | ||
| Q1 24 | $221.9M | $356.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.0K | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $-1.6M | $12.8M |
| 自由现金流率自由现金流/营收 | -2.5% | 13.8% |
| 资本支出强度资本支出/营收 | 2.7% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 0.65× |
| 过去12个月自由现金流最近4个季度 | $5.9M | $24.7M |
8季度趋势，按日历期对齐
经营现金流FCVCEL
| Q4 25 | $98.0K | $15.0M | ||
| Q3 25 | $9.9M | $22.1M | ||
| Q2 25 | $6.3M | $8.2M | ||
| Q1 25 | $-1.4M | $6.6M | ||
| Q4 24 | $14.1M | $22.2M | ||
| Q3 24 | $21.9M | $10.2M | ||
| Q2 24 | $8.2M | $18.5M | ||
| Q1 24 | $12.8M | $7.2M |
自由现金流FCVCEL
| Q4 25 | $-1.6M | $12.8M | ||
| Q3 25 | $5.7M | $19.5M | ||
| Q2 25 | $4.5M | $81.0K | ||
| Q1 25 | $-2.6M | $-7.6M | ||
| Q4 24 | $13.1M | $8.5M | ||
| Q3 24 | $20.8M | $-9.2M | ||
| Q2 24 | $7.3M | $1.8M | ||
| Q1 24 | $12.1M | $-6.8M |
自由现金流率FCVCEL
| Q4 25 | -2.5% | 13.8% | ||
| Q3 25 | 8.0% | 28.8% | ||
| Q2 25 | 6.7% | 0.1% | ||
| Q1 25 | -4.4% | -14.5% | ||
| Q4 24 | 19.0% | 11.2% | ||
| Q3 24 | 24.7% | -15.9% | ||
| Q2 24 | 9.9% | 3.4% | ||
| Q1 24 | 19.8% | -13.3% |
资本支出强度FCVCEL
| Q4 25 | 2.7% | 2.4% | ||
| Q3 25 | 5.9% | 3.9% | ||
| Q2 25 | 2.7% | 12.9% | ||
| Q1 25 | 2.1% | 27.0% | ||
| Q4 24 | 1.4% | 18.3% | ||
| Q3 24 | 1.3% | 33.5% | ||
| Q2 24 | 1.2% | 31.8% | ||
| Q1 24 | 1.0% | 27.3% |
现金转化率FCVCEL
| Q4 25 | — | 0.65× | ||
| Q3 25 | 2.27× | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 11.98× | 1.12× | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 1.43× | — | ||
| Q1 24 | 14.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FC
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
